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Abstract
Researchers familiar with Alzheimer’s disease have often noted the presence of comorbid
anxiety symptomatology. Likewise, the occurrence of anxiety before the development of
Alzheimer’s disease has been prevalent enough to warrant attention. This review seeks to
elaborate on the pathophysiology behind these two conditions, and to accentuate overlapping
aspects that promote a causal relationship between these two pathologies on the macroscopic and
cellular levels. Subsequent evidence will show that these pathologies are not independent of each
other, and that cellular mechanisms of pathology hint at their interrelatedness. Areas requiring
further research that would clarify the relationship between Clinical Anxiety and Alzheimer’s
disease will be identified.
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Anxiety in Alzheimer’s Disease
An Investigation of the Relationship Between Two Pathologies
In the year 1906, a psychiatrist by the name of Alois Alzheimer presented an interesting
medical case at the 37th Meeting of South-West German Psychiatrists (Hippius & Neundörfer,
2003). For the leading clinical practitioners of mental health and neuroanatomy of the area, he
presented the case of a 50-year-old woman who exhibited delusions, sleep and memory
disturbance, and overall cognitive decline until her subsequent death in an immobilized state
(Alzheimer, 1907; Stelzmann, Norman Schnitzlein, & Reed Murtagh, 1995). Upon her death, the
autopsy revealed aggregations of proteins, termed senile plaques, and neurofibrillary tangles of
tau protein. Additional cases were also documented by Alzheimer for patients who suffered the
same fate (Hippius & Neundörfer, 2003).
Over 100 years later, a clear definition for the mechanisms behind this disease’s cause
exceeds the grasp of clinicians and researchers. Cases of Alzheimer’s Disease (AD) that are seen
to be familial have made finding genetic causes simpler. Genes such as the Amyloid-β Precursor
Protein (AβPP) gene and the Presenillin 1 and 2 (PSEN1 and PSEN2 respectively) have been
extensively characterized with respect to their roles in causing AD (Goate, 2006; Kelleher &
Shen, 2017). Yet the genetic form of AD only contributes to less than one percent of all AD
cases by some estimations (Swerdlow, 2007).
This considerable gap in the knowledge behind causes of AD makes a review of certain
risk factors necessary. Anxiety and anxiety symptomatology have been specifically witnessed as
prevalent in the stages prior to and during clinical AD by many researchers and clinicians. For
this reason, a review of the relationship between these two pathologies is necessary to ascertain
the mechanisms by which one neural dysfunction might have a hand in causing the other. The

ANXIETY IN ALZHEIMER’S DISEASE

5

goals of this review are to investigate the viability of clinically relevant anxiety as a causal risk
factor for AD, to identify the role of AD pathophysiology in the dysfunction of anxiety
neurocircuitry, and to characterize the nature of a possible positive feedback mechanism between
anxiety and AD. These goals will be accomplished by an extensive review of the
pathophysiology behind both disorders, specifically referencing areas of overlap. The
conclusions that can currently be defined will be identified, and areas where further research
might lead to a more informed consensus will be accentuated as well.
Methods
To ensure the quality of literature reviewed, a number of simple procedures were
followed during the collection of information to be incorporated in this review. An extensive
search of peer-review journals was undertaken using a broad range of keywords applicable to the
pathophysiology of clinical anxiety (CA) and AD, including clinical anxiety, HPA-axis response,
corticotropic releasing factor or hormone, adrenocorticotropic hormone, cortisol, urocortin, γaminobutyric acid signaling, amyloid-β cascade, cholinergic hypothesis, and tau hypothesis
among others. Two main databases were searched: The Jerry Falwell Library Database and
Google Scholar. These search procedures uncovered 118 peer-reviewed articles that were able to
be included based on their applicability in providing necessary information to answer the abovementioned research questions, specifically regarding the pathophysiology of CA and AD, and the
potential relationship between the two. Articles that did not provide necessary information for
defining the physiology of these two disorders, undertake an investigation of the relationship
between them, or provide useful epidemiological information were excluded.
Anxiety as a Causal Risk Factor for Alzheimer’s Disease
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Introduction. Anxiety is a familiar term to many, yet it can connote a multitude of ideals
depending on perspective. In many instances the term has become so commonplace as to lose its
clinical definition, and perhaps this is a foretold effect of the adoption of a commonplace term
for clinical purposes. For the purposes of this research, it is then necessary to develop a proper
clinical definition of anxiety. Clinical Anxiety (CA) describes affective disorders that can be
characterized by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V)
whose main symptoms involve overall anxiety and feelings of panic due to irrational causes or
for prolonged periods; some examples of disorders falling under this blanket category might
include Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Posttraumatic
Stress Disorder (PTSD), Panic Disorder, and various phobia disorders among others (American
Psychiatric & American Psychiatric Association, 2013). For the purposes of this review, anxiety
symptomatology that warrants clinical treatment or attention might also be considered CA.
Anxiety disorders are widespread, and the combination of the prevalence of multiple disorders
increases the overall occurrence of CA. In a survey population of Americans over the age of 18,
the prevalence of lifetime sufferers of SAD was estimated to be 5.0% (Grant et al., 2005). Other
surveys of American populations have determined the lifetime prevalence for GAD to be
approximately 4.0-7.0% (Kessler, Keller, & Wittchen, 2001). The lifetime prevalence of PTSD
has recently been defined at around 7-8% in a sample of Americans (PTSD, 2018). As will be
discussed later in the study, the potential for anxiety as a risk factor for Alzheimer’ Disease
development puts a considerable proportion of the population at risk. It is therefore necessary to
characterize anxiety conditions and their biological effects to determine the viability of early-tomid-life anxiety as a causal risk factor for AD. Resultantly, it is necessary to determine potential
psychological causes of anxiety and the progression to disorders that fall under the clinical
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category. Furthermore, the mechanism of anxiety’s action must be analyzed on a
pathophysiological level to determine the biological changes in the central nervous system
associated with prolonged stress that might be involved in AD development. Conclusions will be
drawn after research and data are presented that determine the relationship between anxiety and
AD, specifically referencing the debate of whether anxiety is a prodromal symptom of AD or an
independent risk factor.
Evidences for connection in clinical studies. In later sections, the pathophysiology of
Clinical Anxiety will be reviewed and defined on a macroscopic and cellular level. A
characterization of the mechanisms behind these psychiatric dysfunctions will be necessary to
grasp the large and impactful effect anxiety pathology has on the CNS. This vast array of
developmental ramifications has the potential to produce drastic consequences. For this reason,
evidence of these consequences will be identified by analyzing clinical studies wherein anxiety
has led to AD development. This section will introduce convincing evidences that the various
Clinical Anxiety conditions might be risk factors in the development of AD.
Clinicians often make note of the presence of anxiety conditions in older populations.
Seemingly concomitant with these symptoms was the presence of cognitive decline, or mild
cognitive impairments (MCI). It was therefore deemed necessary to investigate both the
existence and nature of a potential relationship between these two conditions; resultantly, several
clinical investigations have been undertaken to identify a relationship. A consideration that must
be made note of regarding a potential relationship between anxiety and MCI is that if a
relationship is identified, the sequential order is still an issue; anxiety could represent a
prodromal symptom of MCI and cognitive decline, or it could induce cognitive damage that
might increase the risk for age-related decline and MCI (Beaudreau & O'Hara, 2008). One study

ANXIETY IN ALZHEIMER’S DISEASE

8

found that older patients complaining of anxiety disturbances performed worse on tests of
working memory than subjects with no reported anxiety, yet the anxiety group still performed
better on this assessment of memory than a group with MCI; this might indicate anxiety as an
intermediate in the progression of cognitive decline, but the results are not conclusive (Christian,
Jean‐Robert, & Lucette, 2004). Another study compared 19 patients with GAD to two other
groups: one of normal subjects and one of those diagnosed with Major Depressive Disorder
(MDD). This study revealed that GAD subjects were impaired in areas of short-term and delayed
memory when compared with physiologically normal individuals, and MDD patients showed
more general cognitive impairments (Mantella et al., 2007). In a sample of older communitydwelling individuals, anxiety was shown to be associated with delayed memory recall; although
the presence of anxiety caused only a slight deficiency, it was also noted in this study that most
of the subjects would not have met psychiatric requirements for a clinical diagnosis of anxiety
disorders (Booth, Schinka, Brown, Mortimer, & Borenstein, 2006). In many instances, clinical
studies attempted to predict cognitive decline using analysis of individuals with common traits of
anxiety; these studies failed to determine a relationship after multi-year longitudinal analysis, yet
in all instances of this technique (as in the previous study), the subjects did not meet the
requirements for clinically diagnosed anxiety, perhaps indicating an essential difference in
populations with CA and elderly populations with anxiety-like traits (Beaudreau & O'Hara,
2008). Another complication often encountered is the presence of MDD in the analyzed
populations, and in some cases, comorbid with CA. This might obscure the causes of cognitive
decline and memory loss in some studies. Some researchers have undertaken screenings to
analyze CA specifically without the presence of MDD as it pertains to decline and memory loss.
One such study made use of regression analysis to show that CA was a significant predictor of
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cognitive decline, and also that memory loss was mediated by anxiety in cognitive decline in a
longitudinal study of 100 participants (Sinoff & Werner, 2003). Another four-year longitudinal
study analyzed patients diagnosed with MDD separated into groups of those diagnosed with
comorbid anxiety (GAD and PD) and those without; the results showed that the CA group had
greater memory deterioration than the group with only MDD (DeLuca et al., 2005). From the
above results, one can conclude that anxiety has a differing effect on the deterioration of
cognition and memory than depression. Furthermore, it is necessary that the form of anxiety
analyzed matches a clinical diagnosis for the deterioration of memory and cognitive impairment
to be pronounced. In many cases, a sub-clinical level of anxiety was seen to facilitate cognitive
performance on appropriate scales of measurement (Beaudreau & O'Hara, 2008). These results
seemingly contradict hypotheses that have anxiety as a risk factor in cognitive decline and
impairment, yet deeper analysis would hold that these results are to be expected according to the
Yerkes-Dodson Law (Teigen, 1994; Yerkes & Dodson, 1908).
Another important consideration in the relationship of CA and progressing deficiency of
memory and cognition, perhaps leading to AD, is the presence of anxiety symptomatology in the
prodromal stage of AD. Perhaps anxiety is simply a prodromal symptom that occurs before
progression to clinically diagnosed AD, and therefore its independence as a risk factor for AD is
invalid. What has recently complicated this question is the absence of prolonged research on the
topic. Many studies are limited in their supposed characterization of the relationship between CA
and AD because they are short-term in length, which would lead one to conclude anxiety is
merely prodromal (Gimson, Schlosser, Huntley, & Marchant, 2018). For example, researchers
accumulated a large amount of data (12,083 subjects were used) from AD treatment centers
across the United States to identify psychological risk factors for the development of AD; among
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other mood disorders, anxiety was found to be a significant predictor of conversion to AD
(Burke, Cadet, Alcide, O'Driscoll, & Maramaldi, 2018). However, this study’s method for
measuring anxiety was self-report by the subjects, and only for a duration of two years prior
(within the range for prodromal symptom presentation). The presence of anxiety
symptomatology as a prodromal process in AD development is not mutually exclusive with CA
also being an independent risk factor for the disease. A 16-year longitudinal analysis of 2,071
individuals observing the development of AD characterized the prodromal stage of cognitive
decline leading to clinically diagnosed AD as commencing 5 to 6 years prior (Wilson, Leurgans,
Boyle, & Bennett, 2011). Therefore, evidence of a correlation between clinically diagnosed midlife anxiety and AD onset in advance of this prodromal stage would be convincing evidence of
CA as an independent risk factor. A review study found four examples of primary research that
investigated this relationship with an average of 10 years between CA diagnosis and ensuing AD
diagnosis; each of the four studies reviewed found a positive relationship between clinically
diagnosed anxiety disorders and AD development at least 10 years from the initial anxiety
assessment (Gimson et al., 2018). This evidence suggests anxiety is capable of standing
independently as a risk factor for AD development (when also correcting for comorbid
depression or controlling for its absence in the abovementioned studies).
Besides mere association of these two pathological conditions, further evidences have
been uncovered with clinical research of the brain structures and processes that also support the
hypothesis of CA as an independent risk factor rather than prodromal symptom. Researchers
utilized imaging data from the Alzheimer’s Disease Neuroimaging Database (ADNI) to compare
effects of anxiety on the conversion of amnestic mild cognitive impairment (aMCI) to AD; after
controlling for depression, cognitive decline, and baseline atrophy rates of AD regions of interest
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(ROI, such as the hippocampus, amygdala, etc.), this study confirmed that anxiety
symptomatology significantly predicted conversion to AD (Mah, Binns, & Steffens, 2015).
Furthermore, anxiety also was significantly associated with more pronounced atrophy of the
entorhinal cortex (EC), and it is hypothesized that anxiety mediates its deteriorative effects via
this process (Mah et al., 2015). Other researchers undertook the similar research goal of
identifying factors that might prognosticate the development of AD from MCI. One such study
analyzed multiple factors, including mood-related depression, motivation-related depression, and
anxiety symptomatology; the data found that persons with anxiety and MCI developed AD at
twice the rate of those with MCI but no anxiety (Palmer et al., 2007).
Psychological Considerations. The various psychological diagnoses described by the
blanket phrase Clinical Anxiety are numerous and distinct from each other; likewise, the causes
of anxiety conditions are similarly distinct on a patient-by-patient basis (or client-by-client basis,
following the counseling customs of terminology). Certain psychological considerations are
necessary to understand the development of CA pathologies and the often environmental causes
associated with its development. The Biopsychosocial Model is perhaps the most popular
approach in defining the various methods by which psychiatric pathologies occur; this holistic
approach takes into account the biological aspects (such as genetics, developmental
abnormalities, neurotransmitter abnormalities), the psychological aspects (client perceptions,
personality, ego strength, self-esteem), and social aspects (life experiences, social networks and
support, cultural norms) (Engel, 1980). The biological aspect of anxiety pathology is essential to
defining the relationship of CA as a potential independent risk factor for AD development, and
therefore it will be elaborated on in the “Pathophysiology” section below.
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In order to describe the psychological factors that often correlate with the development of
anxiety, several studies have undertaken research that attempted to characterize clients that deal
with these pathologies. One study’s goal was to identify certain personality traits that put one at
risk for CA development. It was determined that anxiety is predicted to develop more frequently
in individuals with increased novelty-seeking, harm-avoidance, and persistence, as well as
decreased self-directedness (Matsudaira & Kitamura, 2006). The self-directedness attribute is
inclusive of several attributes some consider essential in the coping method paradigm, such as
self-esteem, locus of control, and problem-solving. Low self-esteem has long been associated
with numerous pathological conditions, including anxiety (Leary, Schreindorfer, & Haupt,
1995). Locus of control is an essential concept commonly referred to in psychological studies of
personality traits, and it is especially noted in many cases as having pertinent impact on an
individual’s ability to cope with certain stressors. Locus of control is a researcher’s concept
developed to define individuals’ cognitions and ideals that cause them to attribute the source of
reinforcement to one of two categories. Two paradigms exist for this aspect of personality: an
individual perceives occurrences as under the control of the individual (an internal locus of
control), or an individual perceives occurrences as due to chance, fate, or others (an external
locus of control) (Archer, 1979). The connection between externality (having an external locus
of control) and anxiety has long been under investigation. A meta-analysis of these investigations
has identified a significant correlation between externality and trait anxiety (anxiety that is an
aspect of one’s nature and personality, contrasted with state anxiety which is dependent on one’s
reaction to specific adverse situations). This study also found that for internality, there is a
significant negative correlation with trait anxiety (Archer, 1979).

ANXIETY IN ALZHEIMER’S DISEASE

13

Also applicable to the development of CA disorders are social aspects, or stressors, that
cause a decompensation by the client, allowing the deterioration into a psychiatric disorder. One
category of events that might cause social distress are developmental crises. Developmental
crises are various crises of personality that one encounters throughout a lifetime; developmental
crises present themselves at various stages, and represent a struggle to overcome certain fears
that are prominent at the specified age. Most psychologists still recognize the work of Erik
Erikson, and his eight stages of psychosocial development as the most applicable theory in the
field of developmental crises (Erikson, 1968). Developmental crises are a more specific category
of adverse life encounters, also referred to as crises. The occurrence of a psychological crisis in
response to an adverse life experience is considered to have four parts according to professionals:
(1) a precipitating event occurs which (2) the individual perceives as threatening or damaging;
(3) this perception leads to emotional distress that in turn (4) causes impairment in functioning
resulting from the failure of the individual’s habitual coping mechanisms (Kanel, 2014). The
concept of ego strength is important in an individual’s handling of a crisis situation. According to
this theory of cognition, ego strength refers to an individual’s psychological capacity to deal with
distressing events and continue to meet one’s needs physically and mentally; ego strength is
diminished by the accumulation of distressing crises, and the addition of more stressors leads to
decompensation by the individual in the form of psychosis, depression, or anxiety (Kanel, 2014).
This state of decompensation and diminished ego strength is referred to as a transcrisis state.
These psychological concerns often have root in the development of certain CA conditions over
prolonged periods of time.
Pathophysiology. The physiology of anxiety is largely related to the stress response,
being that anxiety is the experience of a stressed state for an unnaturally prolonged duration or
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for irrational reasons. The stress response has been extensively characterized by numerous
studies that validate a central role of the endocrine system.
Hypothalamus and amygdala. Corticotropin-releasing factor (CRF) is the hormone that
initiates the cascade leading to the stress response. Over 30 years ago, the 41-amino acid
sequence of CRF was determined after its isolation from ovine hypothalamic extracts; the action
of this newly purified hypothalamic protein was to stimulate the release of corticotropin-like
hormones and β-endorphins (hence the nomenclature) (Vale, Spiess, Rivier, & Rivier, 1981).
Most of the CRF of the CNS was discovered to reside within the soma of neurons in the
paraventricular nucleus (PVN) of the hypothalamus, which most now recognize as a common
characteristic of the hypothalamic tropic hormones that act mostly on the anterior pituitary gland
(Arborelius, Owens, Plotsky, & Nemeroff, 1999). Besides its action on the anterior pituitary,
CRF-producing interneurons are also distributed throughout the CNS in certain regions of the
cerebral cortex (Arborelius et al., 1999). CRF and its respective receptor are also found in high
concentrations in the amygdala, one of the most foundational nuclei of the CNS integral in
emotional response (Gray & Bingaman, 1996) More specifically, the amygdala is essential in
response to negative emotions, most notably fear and anger; many studies have been performed
making use of positron emission tomography (PET) to demonstrate both the central role of the
amygdala in fear response and the absence of fear recognition in facial expression (visual) or in
vocal emotion (auditory) in patients with lesions of the amygdala (Broks et al., 1998; Scott et al.,
1997). From the evidence provided in these studies of the amygdala’s function, and also from the
discovery of CRF in interneurons of the advanced cerebral cortex and the amygdala, the
connection between CRF and the induction of anxiety response becomes more complex. The
presence of CRF innervation in interneurons might suggest the role of CRF not only as a tropic
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hormone for the anterior pituitary, but also as a paramount signaling peptide involved in the
cognitive and behavioral aspects of emotion (Arborelius et al., 1999). Furthermore, animal
studies have revealed that direct introduction of CRF into the amygdala induces a typical anxiety
response, and the administration of receptor antagonists of CRF has anxiolytic results (Gray &
Bingaman, 1996). Thus, the high concentration of CRF and receptors in the amygdala allows the
development of a hypothesis for stress response starting with a stimulus: the distressing stimulus’
detection by the various modes of sensory reception (visual, auditory, perhaps tactile) leads to
signal transduction and activation of the amygdala, inducing CRF interneuron circuits that lead
to the cognitive processing of fear or anxiety. CRF release from the hypothalamic PVN initiates
the pathway of physiological stress response.
Biology and Emotion. There are various theories attempting to describe the conscious
process that allows the experience of emotions. Although the biological occurrences of emotion
can be described, the determination of the correct theory is not as certain, and is perhaps a matter
of timing. The James-Lange theory would have one believe that the initiation of physiological
arousal occurs prior to the induction of cognitive processing of the fearful stimulus, and that the
cognitive processing leading to fear is induced by the consciousness of physiological arousal.
According to the Cannon-Bard theory, the initiation of physiological arousal and the cognitive
processing induced by the amygdala and CRF interneuron communication occur simultaneously,
attributed in large part to signal distribution by the thalamus (the reason this theory is also
referred to as the Thalamic theory) (Cannon, 1931). The Schacter-Singer two factor theory of
emotion might postulate that physiological arousal alone is insufficient to produce an anxiety
response, and that the cognitive label given to a stimulus (supposedly by CRF interneuron
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communication) is necessary to produce the emotional experience of anxiety and fear
specifically (Schachter & Singer, 1962).
The HPA-axis and stress response. Regardless, it is clear that CRF is involved in both
the cognition of anxiety as well as the physiological changes associated with it. As noted, CRF is
released from the PVN of the hypothalamus to act on the anterior pituitary; much like other
hypothalamic tropic hormones, it is transported to have effect on the pituitary via the
hypothalamic-hypophyseal portal system, which induces the release of adrenocorticotropic
hormone (ACTH) from the anterior pituitary (Plotsky, 1991). ACTH reaches the adrenal glands
via the circulatory system and initiates the release of cortisol, a glucocorticoid that has a wide
variety of effects that result in the physiological responses of prolonged anxiety and stress
(Arborelius et al., 1999; Henckens, Deussing, & Chen, 2016).
CRF and urocortin effects. Before elaboration of the exact physiological effects of this
hypothalamic-pituitary-adrenal (HPA) axis, another crucial signaling molecule operating in
unison with (or perhaps as a counter to) CRF must be described to explain its role in the
physiology of anxiety cognition. After the sequencing of CRF, a related neuropeptide with 45%
sequence identity to CRF was isolated and named urocortin (UCN) (Vaughan et al., 1995). Three
subtypes of this neuropeptide were eventually defined: urocortin 1 (UCN1), UCN2, and UCN3,
the latter two also known as stresscopin-related peptide and stresscopin, respectively
(Dautzenberg & Hauger, 2002). Also essential in defining stress physiology was the parallel
discovery of the receptors on which these neuropeptides (CRF and the various UCNs) act. Two
types of receptors, CRF receptor 1 (CRFR1) and CRFR2 were identified and sequenced as
proteins with seven transmembrane helix domains; these typical G protein coupled receptors
(GPCRs) mediate their action by coupling with Gs to stimulate alterations in cyclic adenosine
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monophosphate (cAMP) concentrations in the targeted cells (Chang, Pearse, O'Connell, &
Rosenfeld, 1993; Perrin et al., 1995). The difference between these two types of the CRF
receptor occur in their respective ligand-binding specificities. The CRFR1 receptor has high
affinity for CRF; UCN1 binds both receptors with equal specificity, and UCN2/3 both prefer
CRFR2 (Henckens et al., 2016). The activation of CRFR1 by its respective ligands is associated
with increased anxiety (anxiogenesis), and the introduction of CRFR1 receptor antagonists has
been shown to decrease anxiogenic motor activity in animal studies (Henckens et al., 2016;
Zorrilla, Valdez, Nozulak, Koob, & Markou, 2002). For this reason, many have hypothesized
that overstimulation of CRFR1 is central to the development of various psychological anxiety
pathologies, and the production of receptor antagonists of CRFR1 will have beneficial anxiolytic
effects (Henckens et al., 2016). The role of CRFR2 is less certain among researchers, although
most concede that it is still as essential as CRFR1 in the physiology of anxiety. Some postulate
that the action of CRFR2 G protein signaling is to contradict the effects of CRFR1 signaling by
returning the individual from a stress-induced state to a normal physiological homeostasis.
Certain murine studies lead to this conclusion, as mice lacking functional CRFR2 exhibited an
anxiogenic phenotype as well as increased serotonin (5-HT) turnover and decreased 5-HT levels,
especially in the dorsal raphe nucleus (RN) (Issler et al., 2014). This indicated an inability of
these knockout mice to cope after stressful stimuli for prolonged periods of time when compared
with wildtype individuals. Other researchers hypothesized that the CRFR2 pathway represents a
separate mechanism of dealing with stressful stimuli. Whereas the CRFR1 signaling triggers
active stress compensation, CRFR2 might initiate a passive, decompensation response; studies
cite the involvement of CRFR2 signaling with increased serotonin concentrations in the dorsal
RN as evidence (Maier & Watkins, 2005). This physiological mechanism is presumed to be the
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biological foundation for learned helplessness in response to a stressor that cannot be coped with
(Maier & Watkins, 2005). Another consideration in the function of CRF and the related peptides
is the presence of corticotropin releasing factor binding protein (CRF-BP). Subsequently, this
protein binds and limits the concentration of available ligand for the CRFR receptors; the
positive modulation of its activity by glucocorticoids might suggests its role in facilitating the
negative feedback mechanism of the HPA axis (Behan et al., 1995). As mentioned, both types of
CRFR GPCRs associate with Gs, and therefore initiate the classic cAMP/ protein kinase A
(PKA) pathway. The downstream targets subsequently are cAMP-response element (CRE) genes
that induce dendrite stabilization, ion channel permeability, and transcription of additional CRE
binding protein (CREB, an essential component in the pathway of long-term potentiation)
(Barco, Alarcon, & Kandel, 2002; Henckens et al., 2016). The synaptic modulation that occurs as
a result of dendrite stabilization and long-term potentiation is an indicator of the drastic effects
CRF signaling might have on cognitive processing over a long duration. After ligand binding to
the CRFRs and signal transduction, GPCR kinases (GRKs) phosphorylate the receptors and
dissociate them from the G proteins to halt signal transduction. β-arrestins then internalize the
CRFRs from the cell surface which are either returned to the cell surface after dephosphorylation
in the presence of lower signal molecule concentration, or degraded in lysosomes in response to
prolonged increased signal molecule concentration (Benovic, Strasser, Caron, & Lefkowitz,
1986; Kelly, Bailey, & Henderson, 2008). Researchers have noticed an anomaly occurring in
some cases when the phosphorylated CRFRs are not internalized despite the proper action of the
GRKs. It is hypothesized that the failure of this desensitization to stressful signals is what might
be the cause of debilitating anxiety (Henckens et al., 2016).
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Cortisol and gonadotropin receptor signaling. As previously mentioned, the end result
of HPA axis activation is the production of cortisol by the adrenal cortex. Researchers first noted
the importance of cortisol signaling in the production of the stress response after administration
of cortisol was found to cause hypertension and elevated fasting blood glucose levels
(Whitworth, Saines, & Scoggins, 1984). The mechanism of cortisol’s action was soon to be
defined. Further investigation unveiled the receptor that mediates cortisol’s genomic effects. As a
steroid hormone, it was no surprise that an intracellular receptor of the nuclear receptor
superfamily recognized cortisol as its ligand. The glucocorticoid receptor (GR) was identified as
this steroid hormone receptor (Kadmiel & Cidlowski, 2013). It is important to note that while
most of the genes affected by GR binding are positively regulated, some genes are
downregulated, including the gene producing β-arrestin (the molecule essential for
internalization of CRFRs) (Kadmiel & Cidlowski, 2013; Oakley, Revollo, & Cidlowski, 2012).
This relationship could indicate the potential negative effects of cortisol signaling on essential
processes important for the downregulation of CRFR receptors to prevent prolonged anxiety.
Cortisol signaling has several classic effects that are recognized as part of the stress response. In
hepatocytes, cortisol and GR gene activation result in the initiation of glycogenolysis and
gluconeogenesis, a cause of the previously mentioned increased blood glucose during fasting
(Kadmiel & Cidlowski, 2013). Glucocorticoid signaling in blood vessels inhibits vasodilator
production, leading to the commonly noted hypertension effects. Cortisol signaling is also
essential in inducing immunosuppression, commonly seen during prolonged periods of distress;
consequently, glucocorticoids and derivatives are often used to suppress the immune system
during organ transplants (Kadmiel & Cidlowski, 2013).
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The effects of cortisol and glucocorticoid signaling on the nervous system are noteworthy
in that they are active components of some psychiatric dysfunctions. Increased levels of cortisol
and GR response signaling have been witnessed in certain mood/affective disorders such as
PTSD (Kadmiel & Cidlowski, 2013). Certain murine studies have shown that individuals with
non-functional GR protein in the nervous system display impaired response to distressing signals
as well as decreased anxiety (Tronche et al., 1999). Other researchers found that overexpression
of GR in the early life of murine populations altered the patterns of gene expression for the
lifetime of the animal, and led to increased anxiety (Wei et al., 2012).
Clinical studies of cortisol signaling. Following the hypothesis of altered cortisol stress
response cell signaling as a potential source of psychiatric dysfunctions, investigators undertook
several clinical studies to identify human correlates for the murine studies that were performed.
One such study researched prospectively by determining the amount of glucocorticoid receptors
in military servicemen and women prior to, 1 month after, and 6 months after deployment; those
diagnosed with drastic PTSD symptoms 6 months post-deployment had exhibited significantly
higher numbers of GR before deployment occurred when compared with a control sample of
psychologically normal servicemen (Van Zuiden et al., 2011). Other researchers have
hypothesized a “blunted” cortisol response in those with anxiety disorders as a potential cause of
the psychiatric disorder. A study of women reporting childhood physical abuse reported a
blunted cortisol response to the Trier Social Stress Test (TSST), a common evidenced-based
method for inducing stress response in human subjects (Carpenter, Shattuck, Tyrka, Geracioti, &
Price, 2011). It is notable that this study included only women that had been physically abused as
children, but had minimal or no current psychopathologies. In continuation of this postulate,
other studies have attempted to replicate this blunted cortisol effect finding with samples of
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diagnosed anxiety patients. A meta-analysis of 732 diagnosed CA patients (including patients
with PTSD, SAD, and PD) had limited success in replicating the blunted response. This study
found that women with anxiety disorders in general exhibited a blunted cortisol stress response
to the TSST, while men with SAD had an increased cortisol response (Zorn et al., 2017).
Cortisol effects on memory and cognition. As has been shown, uncovering the cortisol
and glucocorticoid receptor signaling processes has been of paramount importance in defining
the physiological response to stressful stimuli; for this reason, many researchers continue to form
hypotheses that attribute a central role to these signaling pathways in pathological stress
conditions. Some studies have identified cortisol and its signaling pathways as having a role in
certain brain structure and HPA-axis modifications that might lead to pathological anxiety
conditions. One revelation contributing to this theory was the discovery of high GR
concentrations in the hippocampus and limbic system compared with the rest of the structures in
the brain (de Kloet, Joëls, & Holsboer, 2005). This is indicative of the vulnerability of the
hippocampus (an essential structure in memory storage and retrieval) to altered concentrations of
cortisol. The effects were evident in the hippocampal atrophy that ensues upon exposure to
excessive cortisol (Goosens & Sapolosky, 2007). Researchers thus identified a glucocorticoid
cascade hypothesis because the damaging of hippocampus from excessive cortisol exposure
results in the inability of the brain to regulate cortisol secretion via the normal negative feedback
mechanism, leading to increased atrophy; it is further hypothesized that the negative
consequences of this debilitating pathway are mediated by cortisol induced neurotoxic effects
and even neuroinflammation (Frodl & O'Keane, 2013). Other researchers directly performed
experiments that manipulated the concentration of cortisol in human populations and analyzed
the effect of these altered concentrations on cognition and memory. One such study made use of
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a younger human population to test this hypothesis; using a method of decreasing cortisol
concentration and then restoring it, this study found that after a decrease in cortisol, memory
recall was impaired compared to the placebo-treated control group, and also that recall was
restored after cortisol levels were restored (Lupien et al., 2002). Furthermore, when researchers
increased the concentration of cortisol in the morning (a time when the circadian rhythm has
cortisol levels at their peak), the alteration in concentration had drastic negative effects on
cognition, while injection of the same concentration in the afternoon (when cortisol levels are at
a daily low) had positive effects on cognition (Lupien et al., 2002). A meta-analysis of cortisol
administration studies and the effects thereof on memory performance tested similar conditions
of cortisol administration. This review found that patients administered cortisol before retrieval
was tested saw a decrease in memory performance, while administration before learning
occurred had no effect on average; this study was able to replicate the discoveries of the
previously mentioned researchers, finding that cortisol administration in the morning impaired
memory while cortisol administration in the afternoon enhanced it (Het, Ramlow, & Wolf,
2005). It appears that an increase in cortisol concentration above the naturally occurring
maximum concentration functions to impair memory and cognition, while maintenance of
cortisol concentrations at a certain maximum is sufficient to enhance cognitive performance and
recall according to the results of these studies. These evidences combined with other data
collected on memory performance given certain cortisol concentrations have led to the
development of an optimal concentration theory of cortisol’s effect. A bell curve depicting this
hypothesis visually displays that memory can be impaired when cortisol levels fall below a
certain concentration, or rise far above the optimal concentration (Goosens & Sapolosky, 2007).
Because of the high concentration of GRs in the hippocampus, it was presumed that the effect of

ANXIETY IN ALZHEIMER’S DISEASE

23

cortisol on learning and memory was mediated by its action in this brain region; likewise,
chronic stress (prolonged elevated cortisol concentration) rather than sudden changes in cortisol
levels (as had been tested in the previous studies) was discovered to have a more consistent
effect of impairing memory performance. Chronic stress was shown to impair hippocampaldependent spatial learning in classic tests of murine spatial learning performance (Goosens &
Sapolosky, 2007). Similar deficits have been recognized in studies of humans with chronic
stress, specifically pertaining to episodic memory (Bergdahl, Larsson, Nilsson, ÅHlstrÖM, &
Nyberg, 2005). Glucocorticoids (GCs) were identified as the likely cause of these adverse
effects. Removal of adrenal glands prior to chronic stress was able to prevent these stress-caused
memory impairments, and prolonged GC injection (simulating chronic stress) was sufficient to
produce the same hippocampal-centered memory task impairments (Goosens & Sapolosky,
2007). Therefore, prolonged activation of the HPA axis and exposure to cortisol (as seen in
Clinical Anxiety conditions) is sufficient to produce certain memory impairments and has
adverse effects on brain structures essential in cognitive performance.
GABAergic communication and anxiety. Other essential signaling molecules that are
crucial to understanding the pathology behind anxiety disorders are neurotransmitters. More
specifically, many researchers have identified the central role of γ-aminobutyric acid (GABA)
signaling and GABAergic neural pathways in the regulation of anxiety cognition. Several
GABA-related compounds have been tested for their various effects regarding the subjective
experience of anxiety; it was shown that GABA agonist administration (for example, many types
of benzodiazepines) was sufficient to produce anxiolytic effects, while the administration of
GABA antagonists and chloride ion channel blockers exhibited an anxiogenic response (Kalueff
& Nutt, 1996). GABA is the main inhibitory neurotransmitter of the nervous system, often seen
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modulating the effects of glutamine, the main excitatory neurotransmitter of the CNS. In the
various nuclei of the amygdala, GABAergic modulation is essential to the inhibition of overanxious presentations; glutamatergic communication between the previously mentioned BLA
and the central nucleus (CeA) of the centromedial amygdala complex is modulated by additional
inhibitory GABAergic communication from certain interneurons (referred to as intercalated
neurons) to inhibit the CeA (Nuss, 2015). Likewise, it has been suggested that PFC inhibitory
regulation of the BLA and subsequently the CeA is necessary in attenuating the spread of neural
output from the amygdala (Nuss, 2015). Investigating the role of various medial PFC nuclei,
researchers discovered that the lesion of these areas in murine studies disabled the extinction of
fear, and thus produced a persistent anxious emotional response. Likewise, the higher dorsal
nuclei exhibited more activation in the cognitive processing of anxiety and fear, while lower
ventral nuclei exhibited more influence on the emotional presentation of anxiety (Etkin, 2009).
The main clinical target of various pharmacological treatments for anxiety has largely been the
GABAA receptors. These receptors are ionotropic chloride ion channels that induce the
hyperpolarization of the postsynaptic membranes being acted upon. The receptor itself is a fivesubunit transporter with two α subunits, two β subunits, and one γ subunit; two GABA molecules
are capable of binding between the α and β subunits that exhibit positive cooperativity, allowing
the opening of a centrally located ion channel (Sieghart, 2006). It was also discovered that
benzodiazepines bind allosterically between the α and γ subunits, and increase the cooperativity
of GABA binding to the two active sites; the ease of channel opening provided by
benzodiazepines leads to increasing likelihood of inhibition and attenuation of anxiety (Sigel &
Ernst, 2018). Various negative side effects have been exhibited with the use of benzodiazepines
however, mainly including sedative effects such as ataxia and varied resting/sleeping posture in
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studies of primates (Duke et al., 2018). Therefore, further investigation of different agonists for
the GABAA receptor that act on different allosteric areas would prove necessary both for
developing new clinical applications and understanding the role of this receptor in the pathology
of anxiety. Neurosteroids were widely investigated for their role as endogenous modulators of
GABAA receptors; they were seen to act as positive allosteric molecules supporting the
association of GABA, and were identified as capable of opening the GABAA channels
themselves (Nuss, 2015). To identify the potential role of neurosteroids in pathological anxiety,
researchers compared CA patients (exhibiting GAD) and healthy controls; it was determined that
CA patients had significantly lower plasma levels of the neurosteriod pregnenolone than did the
controls (Semeniuk, Jhangri, & Le Mellédo, 2001). The neurosteriod hypothesis of pathological
anxiety is further supported by evidence that treatment of CA with selective serotonin re-uptake
inhibitors (SSRIs) might exhibit its effectiveness by the molecule causing increased neurosteriod
synthesis in the CNS (Nuss, 2015). Subsequently, molecules that exhibit similar effects as
neurosteriods or promote the synthesis of neurosteriods should produce more natural anxietyattenuating effects. One promising pharmacological solution that follows this logic is etifoxine; it
was shown to produce positive allosteric effects when binding to its unique location on the
GABAA receptor (Schlichter, Rybalchenko, Poisbeau, Verleye, & Gillardin, 2000). Fortunately,
etifoxine was also seen to promote the synthesis of certain neurosteriods, as seen by their
increasing concentrations upon administration of etifoxine even in adrenalectomized and
castrated murine subjects; it is suggested that the neurosteriod-synthesizing effect is due to the
interaction of etifoxine with peripheral benzodiazepine receptors (PBRs) (Verleye et al., 2005).
Other compounds produce anxiolytic effects for different reasons. Tiagabine is a selective
inhibitor of GABA transporter 1 (GAT-1, responsible for re-uptake of GABA from the synapse);
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a mutation in this specific transporter that might be responsible for a decrease in GABA
concentration at the synapse is a promising genetic candidate for the cause of anxiety disorders
(Thoeringer et al., 2009).
CNS structural changes in anxiety. Magnetic resonance imaging (MRI) has proven a
useful tool in determining the exact effects on brain structure that Clinical Anxiety conditions
can produce due to prolonged distress. Data has shown that higher PTSD scores are associated
with increasingly pronounced hippocampal atrophy, as well as reduced total white matter volume
when compared with data from pathologically normal individuals (Villarreal et al., 2002;
Weniger, Lange, Sachsse, & Irle, 2008). It is notable that many researchers have also found
hippocampal atrophy to be a common presymptomatic occurrence in the development of AD,
and this brain structure is severely atrophied throughout the progression of the disease as well
(Carlesimo et al., 2015; Fox et al., 1996). Similar to hippocampal atrophy, data collected on
other brain regions has shown that prefrontal lobe areas and other cortices of the cerebrum show
significant atrophy as well with age; these regions contain high levels of GR, indicating the
potential importance of the role of the HPA axis in this age-related deterioration (Goosens &
Sapolosky, 2007). These regions are important targets of the cholinergically supplied reticular
activating system (RAS), and the deterioration of neural communication in these regions is a
primary component of AD pathology (see “Cholinergic Hypothesis” in Pathophysiology of
Alzheimer’s Disease section) (Hampel et al., 2019).
In murine studies, researchers have attempted to define the events leading to neuronal
atrophy and cell death due to HPA axis activity. Prolonged GC administration has been shown to
decrease the process of long-term potentiation (LTP), the process long associated with cognitive
development and learning (Pavlides, Watanabe, & McEwen, 1993). The causes of neuronal cell
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death are more difficult to define, but evidence shows that neuronal death related to HPA axis
activation may be due to the interaction of two variables: high GC concentration and age.
Comparing two murine groups, one with increased HPA axis activity and one with normal
activity, the differences in hippocampal volume were only pronounced after the two populations
reached advanced age. The increased HPA activity group showed significant atrophy compared
with the control group (Meaney, Aitken, Bhatnagar, & Sapolsky, 1991). It was also determined
that age-related neuronal death is more pronounced in hippocampal regions that have a higher
density of GC receptors compared with other regions of the hippocampus (Goosens &
Sapolosky, 2007).
These brain region changes (specifically hippocampal atrophy) have been identified by
researchers as a result of the development of pathological psychiatric conditions (namely PTSD)
due to childhood abuse and maltreatment; it is hypothesized that maltreatment during a young
age increases the CNS susceptibility to age-related changes or negative reactions to adulthood
stressors that in turn have detrimental effects on the function of the HPA-axis (Frodl & O'Keane,
2013). As previously mentioned, the glucocorticoid cascade hypothesis, whereby hippocampal
atrophy and decreased negative feedback leads to increased cortisol secretion and further
atrophy, is essential in describing the transition from CA to cognitive deficits seen in AD. The
consequences of this pathway are exacerbated by the neurotoxic effects of cortisol and
neuroinflammation (Frodl & O'Keane, 2013). This mechanism of pathology hints at anxiety’s
role in the Tau Hypothesis of AD pathology (discussed later), which relies on the dysfunction of
the CNS immune system in attempting to combat the effects of neuroinflammation, leading to
the deregulation of certain kinases that cause tau phosphorylation and neurofibrillary tangle
(NFT) formation (Maccioni, Farías, Morales, & Navarrete, 2010).
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The Development of Anxiety in Alzheimer’s Disease
Introduction. Among the total population of Americans today, 5.3 million are currently
afflicted with Alzheimer’s Disease (AD). By 2050, the projected rate of new cases of AD
diagnosis will amount to 1 million individuals per year (Alzheimer’s, 2015). Alzheimer’s
Disease is widespread in its affliction of individuals in western societies, and seems to be a tradeoff of the long life that many in such Western countries are privileged to reach due in large part
to advanced developments in medical care. For this reason, AD has become the focus of many
researchers and studies in the developed west. This pathology came to the forefront of clinical
attention after its first diagnosis in the year 1906; Alois Alzheimer first noted an elderly female
patient at his psychiatry institute in a bizarre demented condition of delusion and memory loss,
and upon her death, discovered the neurofibrillary tangles and amyloid-β plaques that were to
become all too familiar in the ensuing years (Stelzmann et al., 1995). Highlighted by the many
clinicians familiar with this original case is the fact that this original patient is better
characterized by the genetic form of the disease, Autosomal Dominant Alzheimer’s Disease
(ADAD). The reasoning behind this (also the reasoning for another name of ADAD being Early
Onset AD) is that the patient developed these characteristics earlier than 65 years of age
(Stelzmann et al., 1995). ADAD has been extensively characterized as the result of two different
genes: AβPP and PSEN1, both of which cause the AD pathology from dysfunction of the
amyloid-β precursor protein processing via the action of enzyme γ-secretase (Goate, 2006;
Kelleher & Shen, 2017). The non-genetic form of the disease is remarkably harder to
characterize with respect to causes, and the exact action of such structures as amyloid-β (Aβ)
plaques and their effects on the progressions and impairments associated with AD are debated by
many researchers. Some voice the opinion of the aggregation of these plaques directly causing
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the pathology, and others opt for a theory that holds reactive oxygen species (ROS) produced
from these aggregations more responsible for neuronal degradation in the central nervous system
(Aminzadeh, Roghani, Sarfallah, & Riazi, 2018; Seino et al., 2018). Some researchers highlight
the dysfunction of cholinergic communication as essential in disease development, while other
focus on the processes of tau phosphorylation. For these reasons, a review of these topics is
necessary to determine where exactly the scientific community stands in characterizing this
pathology, and also in developing treatments effective against this debilitating disease.
Subsequently, the physiological changes caused by AD that lend themselves to involvement with
the pathways of CA dysfunction will be analyzed.
Pathophysiology. The difficulty in finding effective treatments for Alzheimer’s Disease
is in large part due to the lack of a clear pathophysiological mechanism that defines the cellular
complications involved in causing the symptoms of AD. Many researchers have found promising
hypotheses, yet in certain areas these hypotheses are unable to account for some of the cellular
complications seen in AD. Despite this indeterminacy, the most widely accepted theory for AD
progression is the amyloid-β cascade hypothesis
Amyloid-β Cascade Hypothesis. The amyloid-β precursor protein (AβPP) is encoded by
the gene of the same name, mapping to the 21st chromosome; this protein had long been the
suspect of AD pathology because of the correlation between Down syndrome (Trisomy 21) and
the development of Early Onset AD (it is this gene’s various mutations that are responsible for
the genetic form, ADAD) (George-Hyslop et al., 1987; Information, 2018). An in depth look at
this locus of pathology allowed a more sophisticated understanding of the complex enzymatic
pathway behind AD. The AβPP gene product is habitually cleaved in one of two pathways: by
either α-secretase or β-secretase, the latter of which is more often expressed in the CNS; after
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ensuing cleavage by β-secretase, one of the two protein fragments (the C99 fragment) is
aberrantly cleaved by γ-secretase, causing an abnormal amount of Aβ42 with respect to Aβ40
levels (Goate, 2006; Kumar, Singh, & Ekavali, 2015; Salomone, Caraci, Leggio, Fedotova, &
Drago, 2012). The supposed main contributor to pathological symptoms is the aggregation of
these Aβ42 peptides into oligomers, leading to their coalescence into β-sheets and ensuing
deposition into senile plaques characteristic of AD (Hardy, 2009; Kumar et al., 2015; Seino et
al., 2018). These Aβ oligomers cause oxidative damage of cellular structures mediated by ROS,
and also increase tau phosphorylation, specifically impairing the synaptic structures of neurons
(Kumar et al., 2015). Aβ oligomers are also involved with the destruction of membranes high in
cholesterol content, specifically those of the oligodendrocytes, glial cells that myelinate axons in
the CNS (Roth, Ramírez, Alarcón, & Von Bernhardi, 2005). The loss of myelination likely
results in some of the characteristics of an AD-afflicted CNS, yet more profound debilitating
effects are produced by the mechanism of Aβ oligomers’ interference specifically in the cells
surrounding the extracellular matrix at the synaptic gap. Astrocytes are the glial cells that are
perhaps the most prototypical cells of the various neuron supporting cells; they exert their effects
on the neurons in part by regulating the blood-brain barrier, and also by controlling the molecular
and ionic concentrations of the synapse whilst also holding the pre- and post-synaptic neurons in
appropriate articulation with each other (Kimelberg & Nedergaard, 2010). At a certain point in
Aβ oligomer production and concentration in an afflicted neuron, its release to the extracellular
matrix (ECM) will become inevitable, putting them in high concentration to act on the
neighboring astrocytes in support of the neuron; a certain subtype of acetylcholinergic receptor
(α7 nicotinic) directly binds the Αβ oligomers on the surface of the astrocytes (Kumar et al.,
2015; Talantova et al., 2013). The binding of oligomers signals an intracellular increase of
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calcium ions (Ca2+) and their influx into the astrocytes, which mediates calcium-dependent
glutamate release to the ECM (Talantova et al., 2013). This effect of Aβ oligomers and the
increased glutamate concentration is sufficient to activate the extracellular N-methyl d-aspartate
receptors (eNMDARs) on the neurons intimately involved with the astrocyte under analysis; the
intracellular effects on the surrounding neurons is an increase in calcium, which is known to
have various adverse effects intracellularly depending on the concentration, especially with
respect to the mitochondrial system (Talantova et al., 2013). The end result is the expulsion of
ROS from mitochondria, causing oxidative damage, caspase 3 (a known apoptotic protein)
activation, and tau hyperphosphorylation, all of which result in the loss of synaptic spines and
therefore communication between pre- and post-synaptic neurons in close proximity to the
dysfunctional astrocyte (Kumar et al., 2015; Talantova et al., 2013).
Cholinergic Hypothesis. Some researchers may find the amyloid-β cascade hypothesis to
be less inclusive of some data among AD patients that can be more simply explained with the
use of other theories. Because the majority of current clinically approved treatments for AD
involve aspects of cholinergic synapse communication, researchers have formulated the
cholinergic hypothesis, and their claims have largely been substantiated by certain evidences in
the pathophysiology of AD patients. The role of brain acetylcholine content and its involvement
in cognition and memory has been under investigation for over 40 years. Studies made use of the
drug scopolamine (which functions as a nervous system cholinergic blockage) to compare young
subjects treated with the drug with older subjects left untreated. The ensuing performances of
both groups on examinations of cognitions and memory were highly comparable, indicating a
possible link between loss of cholinergic synaptic communication and age-related dementia
(Drachman & Leavitt, 1974). Other researchers found a lack of acetylcholine (ACh) synthetic
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enzymes in the brain samples of deceased AD patients; additional relationships were uncovered
such as cholinergic dysfunction correlating with memory loss, and supplementary cholinergic
stimulation correlating with memory improvements among aged subjects. These findings led to
the formulation of the cholinergic hypothesis in its fledgling state, before the exact
pathophysiology was understood (Bartus, Dean, Beer, & Lippa, 1982; Hampel et al., 2019). The
cholinergic hypothesis became more specific in scope with the discovery of the nucleus basalis
of Meynert (NbM) as the central source for cholinergic innervation to the cerebral cortex, and
also the atrophy of neurons in this very brain region among AD patients (Mesulam & Van
Hoesen, 1976; Whitehouse et al., 1982). The current understanding of the cholinergic hypothesis
and the actions of the cholinergic synapses in the processes of memory as well as their
dysfunction in cognitively impaired patients (such as those with AD) mainly relate to the NbM
brain region. It is notable that the NbM is paramount in providing innervation to the cerebral
cortex as part of the RAS, which many cite as essential for consciousness and higher level
cognitions including memory (Yeo, Chang, & Jang, 2013). The Ch4 neurons of the NbM form
the nucleus basalis, which witnesses significant loss and shrinkage of cholinergic neurons
(Kordower, Gash, Bothwell, Hersh, & Mufson, 1989). These same neurons often appear to be the
targets of NFTs in AD; the high density of NFTs in the NbM Ch4 neurons appears to be the
cause of synaptic destruction, further supporting the notion that loss of cholinergic innervations
(especially those innervations that link the “primitive brain” regions to the complex cerebral
cortex via the RAS) is the cause of observable AD pathology (Hampel et al., 2019).
According to the provided evidence from many researchers, and also according to the
conventional treatment of AD with cholinesterase inhibitors, it should be evident that intact
cholinergic innervation is essential for normal cognitive processes, and also that dysfunction in
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the cholinergic innervation to the cerebral cortex is one of the trademarks of AD-affected brains
that causes the common pathologies of cognitive impairment and memory loss. Although most
researchers favor one of the above hypotheses over the other, it does not appear that the two
previously mentioned hypotheses need be mutually exclusive of each other. In fact, there is
substantial evidence that might indicate the exact opposite. Studies have shown that high
concentrations of Aβ were associated with increased loss of cholinergic innervation, and also that
Aβ levels showed positive correlation with brain atrophy in specific NbM regions (Hampel et al.,
2019; Kerbler et al., 2015). More research is required to further affirm the relationship between
these two hypotheses, yet it would appear that the expression of Aβ cascade processes that lead
to ROS release and apoptotic pathways among neurons at dysfunctional synapses could be
localized specifically for expression in cholinergic neurons, especially the synapses thereof
which innervate the cerebral cortex in the RAS.
Tau Hypothesis. Another sect of research on AD pathophysiology is unsure of the
negative effects of the Aβ protein altogether. Some researchers have characterized this protein as
an anti-microbial immune system factor that acts in protection of the CNS (Soscia et al., 2010).
Others also argue that its exhibition in senile plaques late in the progression of AD pathology is
further evidence not of their malevolency, but rather their neuroprotective role (Maccioni et al.,
2010). As mentioned above, NFTs are the other characteristic component of an AD-inflicted
CNS. Resultantly, other researchers opt for the protein component of these NFTs (tau) and its
phosphorylation as the source of AD pathology. The tau protein was originally identified in the
NFTs as a microtubule-associated protein; its modification in AD brains was hypothesized to
result in the instability of the cytoskeletal structure to which it was associated, leading to
neuronal death (Kosik, Joachim, & Selkoe, 1986). The current tau hypothesis postulates that
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NFT formation from tau phosphorylation is not the first step in the neurobiological pathway of
AD pathology, yet it is the common pathway at the end of multiple pathways resulting from
cellular stressors, such as ROS, aberrantly folded proteins, Aβ oligomers, iron overload, and
cholesterol/ low density lipoprotein (LDL) interference (Maccioni et al., 2010). Various studies
have produced evidence of a cascade that ends in NFT formation: the cellular damage caused by
the aforementioned mechanisms results in the activation of microglial cells as part of the immune
response. The production of cytokines then ensues in excess, which cascade into the deregulation
of certain kinases and phosphatases, causing the hyperphosphorylation of the tau protein and
consequent neuronal cell death as mentioned (Fernández, Rojo, Kuljis, & Maccioni, 2008;
Maccioni et al., 2010). Logically, cell death of the neuron with accumulated phosphorylated tau
leads to its expulsion to the ECM, resulting in a cascade of this process in surrounding areas. The
microglial cells are again activated as a result of hyperphosphorylated tau’s presence in the
ECM, triggering the pathway to stimulate cytokine release again, resulting in a positive feedback
loop causing neurodegeneration of the CNS (Maccioni et al., 2010). The specific protein
responsible for the hyperphosphorylation of tau is cyclin-dependent kinase 5 (CDK5). The
protoinflammatory cytokines released by the microglial cells in the CNS are responsible for the
pathway that is deregulated in the AD nervous system that activates CDK5, usually a cell cycle
regulatory kinase, which in turn hyperphosphorylates the tau proteins (Alvarez, Muñoz, &
Maccioni, 2001; Maccioni et al., 2010). One study which made use of murine hippocampal cells
noted that the deregulation of CDK5 can be induced by β-amyloid introduction and lead to
subsequent tau phosphorylation (Alvarez et al., 2001). Other researchers note that Aβ protein
interaction induces inflammatory-like response in astrocytes, and also causes the production of
nerve growth factor (NGF) in these cells; NGF causes an aberrant pathway of signaling via the
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p75 neurotrophin receptor, and results eventually in the hyperphosphorylation of tau proteins
(Sáez, Pehar, Vargas, Barbeito, & Maccioni, 2006). Investigations into the clinical effects of tau
phosphorylation and NFT formation have led to the following conclusions among researchers:
the severity of AD-caused dementia correlates with NFT accumulation in the CNS, there is a
positive relationship between CSF phosphorylated tau concentration and cognitive impairment,
and tau-targeting drugs help decrease cognitive impairment in AD (Maccioni et al., 2010).
The data provided might be analyzed so that the three hypotheses provided can be
considered supplementary to each other. As was mentioned, most Aβ oligomers and aggregates
have been localized to the cholinergic neurons of the CNS, specifically, the RAS. The action of
Aβ oligomers on astrocytes, as defined in the Aβ Cascade Hypothesis section, might be thought
of as occurring mostly in the cholinergic system of CNS neurons. The aberrant actions that this
cascade causes in the destruction at cholinergic synapses also leaks over into tau-phosphorylating
pathways as mentioned above. Part of the effects according to researchers are the overproduction
of NGF at synaptic astrocytes (one can also say the overproduction of glutamate according to the
cascade hypothesis). Both of these chemicals released then cause the hyperphosphorylation of
tau proteins, and likely activation of the inflammatory pathway in neighboring microglial cells,
which induces the release of cytokines which trigger the exact same result. The obvious
connection is a positive feedback mechanism producing further destruction, and leading to the
clinical symptoms of AD as mentioned because of the accumulation of NFTs. This process’s
localization to the cholinergic neurons of the CNS is what causes the specific cognitive and
memory process impairments that are seen in the clinical form of the disease.
Anxiety in Alzheimer’s Disease. Earlier in this review, evidence was presented to
analyze the viability of Clinical Anxiety (CA) as an independent risk factor for the development
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of AD. Several convincing studies indicate this may be a possibility. After the presentation of
AD pathophysiology, it is now necessary to provide evidence supporting the hypothesis that the
aberrant CNS development caused by AD is sufficient to produce comorbid anxiety conditions.
In order for this evidence to be convincing, it should distinctly identify disruption of neural
circuitry sufficient to cause CA, and exclude the possibility of CA development due to
psychological distress associated with the consciousness of an individual’s deteriorative state.
It is well established that anxiety symptomatology is present in many cases of those
affected by AD. One study identified an unusually high proportion of patients with anxiety and
anxiety symptomatology among a population of nursing home residents with dementia (Goyal,
Bergh, Engedal, Kirkevold, & Kirkevold, 2018). The limitation of this study was that it did not
specifically address AD patients but dementia subjects in general. Other researchers sought to
distinguish between AD and other types of dementia. An analysis was performed comparing AD
patients with subjects that had other forms of dementia: Vascular Dementia (VaD) and
Frontotemporal Dementia (FTD) were used. This study’s results were unexpected in that the
patients with other types of dementia than AD exhibited higher proportions of anxiety (Porter et
al., 2003). This research also identified a trend of increasing anxiety as cognitive deterioration
increased (assessed by the Mini Mental Status Examination, or MMSE), and also an increase in
anxiety with earlier age of AD onset (Porter et al., 2003). A hypotheses was made regarding the
reason for the other forms of dementia exhibiting higher anxiety rates: VaD and FTD
increasingly involve frontal lobe deterioration, a region essential in the subjective perception of
anxiety (Porter et al., 2003). An analysis of a cohort of 1,015 AD patients discovered that anxiety
syndromes were some of the most prevalent neuropsychiatric syndromes experienced by this
grouping; furthermore, this study found that these syndromes often occurred at a clinically
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significant level, indicating the severity of AD pathological effects on the CNS (Spalletta et al.,
2010). This study, however, was not able to replicate the findings of Porter et al. that a positive
correlation exists between the severity of AD and the occurrence of anxiety; affective disorders
were the only disorders examined that did not exhibit this correlation (Spalletta et al., 2010).
Researchers have found that certain anxiety symptoms are highly prevalent in AD patients,
including anxious appearance, tension and fidgeting, and sleep disturbance; of the subjects in this
study, however, only 6% met DSM criteria for clinical diagnosis (GAD was the only disorder
measured) (Ferretti, McCurry, Logsdon, Gibbons, & Teri, 2001). This study also found that
anxiety symptoms were associated with increased cognitive impairment, and hypothesized that
treatment of anxiety symptomatology might prove useful for the management of AD (Ferretti et
al., 2001). Further research attempted to characterize the relationship of GAD and AD
specifically. When using the DSM-IV to determine diagnostic criteria, a group of 552 AD
patients exhibited GAD among 15% of its sample; the most common symptoms for this
population were restlessness, irritability, muscle tension, fear, and respiratory disturbances
(Starkstein, Jorge, Petracca, & Robinson, 2007). The genetic form of the disease, Early Onset
Alzheimer’s Disease (EOAD) provides a useful model for the determination of this relationship.
Patients with this form develop AD shortly after the fifth decade of life. Analysis of these
patients provides a model that is certain to exhibit AD (penetrance of the various EOAD gene
mutations is virtually 100%), and therefore eases the characterization of AD comorbid
symptomatology (Tanzi et al., 1996). One study made use of this technique and analyzed the
prevalence of anxiety in patients with EOAD compared with patients who have the more
common Late-Onset Alzheimer’s Disease (LOAD, referred to in this review as the default form).
Findings indicated that anxiety symptomatology was present in both populations of AD patients,
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yet was more prevalent in patients with EOAD as opposed to LOAD (70% versus 27%,
respectively) (Kaiser et al., 2014). Initially, this might be informative of the nature of anxiety in
AD. One might hypothesize that psychological factors are the main cause for the formation of
anxiety in AD, because it could be stated that patients of EOAD have greater consciousness and
understanding of their condition, having expected its development due to its genetic nature in
their cases. LOAD patients, accordingly, might be less conscious of their deteriorative condition
because of the inability to be informed of its development; subsequently this might lead to less
psychological cause for the development of anxiety in AD and explains the results of this study.
This interpretation would need more evidence to support such a hypothesis, and certain
evidences also collected in the aforementioned study might negate its validity. A distinction was
made in the correlates of anxiety for the EOAD and LOAD groups; the anxiety in the EOAD
subset of this study was notably associated with caregiver separation among the patients, while
in the LOAD group anxiety was associated with comorbid psychiatric and behavioral symptoms
(Kaiser et al., 2014). The differences in manifestation of anxiety symptoms might instead be
indicative of the separate causes of AD development in the cases of EOAD as opposed to
LOAD. Again, this hypothesis would also need additional information to clarify its validity.
As evidenced, a substantial relationship exists between AD and subsequent development
of clinically significant anxiety. Simple correlations between the two disorders do not necessarily
indicate causation; rather, investigation into the effects of AD pathology on neural circuits
related to anxiety psychology might provide more convincing evidence. Various studies
performed exhibit certain examples where AD pathology (in the form of Aβ plaques and NFTs)
was discovered to be especially prevalent in nuclei associated with anxiety pathology. One study
of the posthumous anatomy of AD-afflicted individuals allowed for the development of six
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stages that describe the progression of AD; it was determined that the amygdala (mentioned in
the “Anxiety Pathophysiology” section as a crucial nucleus for anxiety generation and
conditioning) is among the first subcortical nuclei to exhibit the characteristic plaques and NFTs
with respect to AD progression in the six stages (Braak & Braak, 1991). Furthermore, the extent
of Aβ and NFT accumulation was seen to increase with the progression of the disease; if it could
be shown that AD pathological interference in the amygdala was sufficient to produce anxiety
symptomatology, this might support the findings of previously mentioned studies that anxiety
was associated with increased cognitive impairment (Braak & Braak, 1991). In order to
determine whether anxiogenic effects occurred in response to Aβ accumulation in the amygdala,
researchers España et al. performed an in depth analysis of fear and anxiety conditioning in ADtransgenic mice, as well as postmortem brain examination of the amygdala in both murine
subjects and humans. It was determined that various AD-transgenic models all exhibited
increased conditioned and instinctive fear responses when compared with wild-type controls
(España et al., 2010; Sterniczuk, Antle, Laferla, & Dyck, 2010). The fear or startle responses
analyzed in murine studies are supposedly analogous to the human subjective experience of
anxiety and fear, but to be sure, these researchers clarified this correlation by noting that
anxiolytic drugs were sufficient to decrease the fear or startle response in transgenic subjects
while having no effect on wild-type individuals (España et al., 2010). Transgenic mice that had
this anxious presentation were seen to also have impaired hippocampal-dependent spatial
memory and notably increased concentrations of Aβ oligomers (España et al., 2010).
Furthermore, immunostaining of autopsied murine subjects revealed the accumulation of Aβ in
either GABAergic interneurons or glutamatergic interneurons of the basolateral amygdala (BLA)
depending on the transgenic model analyzed (APP versus 3xTg-AD, respectively);
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phosphorylated tau was also identified in the 3xTg-AD models (España et al., 2010). Likewise,
analysis of human specimens revealed the presence of Aβ accumulation in GABAergic and
glutamatergic neurons in the BLA of AD brains in significantly increased concentrations
compared with normal individuals; lastly, this study determined that phosphorylation of ERK1
and 2 was increased in the BLA of AD-transgenic mice (España et al., 2010). The ERK/MAPK
signaling pathway in this nucleus is essential for fear acquisition, indicating the role of AD
pathological changes in the positive regulation of its function. Therefore, the findings of this
study provide convincing evidence for the possibility of AD pathology disrupting neural circuitry
intimately involved in the biological processes that induce the psychological experience of
anxiety. Previously described, the amygdala nucleus and neurotransmitter signaling involved
with it is essential in the psychological mechanism of anxiety development. Furthermore, the
accumulation of Aβ in GABAergic neurons of this nucleus might indicate the specificity of AD
pathology in disrupting anxiety signaling when considering the importance of GABAergic
communication in anxiety pathology (see Anxiety Pathophysiology section).
Characterizing the Relationship between Anxiety and Alzheimer’s Disease
Over the course of this review, a plethora of evidence was presented in an effort to
provide a comprehensive understanding of two pathologies: anxiety and Alzheimer’s Disease. In
developing this exhaustive collection of knowledge and evidence on these disorders, various
examples of overlap have been identified between the two diseases that might indicate a causal
relationship between CA and AD development, and also the inverse of that relationship.
Scientific research questions, however, should never start with the goal of proving anything, but
should commence with the ultimate goal of uncovering the truth that already is. If substantial
evidence could be presented that CA is a causal risk factor for AD due to the pathological

ANXIETY IN ALZHEIMER’S DISEASE

41

changes it produces in the CNS, and if further substantial evidence also characterized the disease
morphology seen in AD as significant in disrupting the mechanisms of anxiety, then a unique
relationship would exist between these two pathologies. A positive feedback of sorts would exist
between these two pathologies, with CA leading to AD, and AD in turn producing the side effect
of CA along with mental deterioration. Even with the evidence presented, however, these two
speculations are still rather large ifs. The availability of evidence specifically on the relationship
between these pathologies is relatively low compared to other topics, and the overlaps presented
between the two diseases are not without their complications. In some instances, evidence is
varied with regard to the overlap between these pathologies. In other cases, correlation between
CA and AD might not prove causation of one by the other, but a third factor could be the cause
of both. In this section, evidence presented will be reviewed with these issues in mind, and an
attempt will be made to clarify what conclusions can be stated about the causal relationship of
these two pathologies with the current knowledge base.
Anxiety as a risk factor. Clinical studies were previously identified that tested the
relationship between CA and AD by pure correlation, specifically looking for an increased
chance of AD development when anxiety symptomatology or CA diagnosis was present. A few
of these clinical studies might be considered soft evidence of a relationship, due to the lack of CA
diagnosis among the subjects, and also the identification of cognitive deterioration or MCI rather
than AD as the result. Even so, research identified anxiety symptomatology subjects as having
increased cognitive decline, and decreased performance on appropriate memory assessments
(Booth et al., 2006; Christian et al., 2004). In many instances however, groups of patients with
sub-clinical levels of anxiety failed to exhibit increased rates of cognitive deterioration;
similarly, patients with a clinical diagnosis often displayed this relationship (Beaudreau &
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O'Hara, 2008; Mantella et al., 2007). Studies that controlled for additional factors such as MDD
produced further convincing evidence of a relationship between CA and cognitive decline or
memory deterioration (DeLuca et al., 2005; Sinoff & Werner, 2003). The evidence presented in
these studies leads to the conclusion that anxiety has differing deteriorative effects on cognition
than does MDD, and also that a clinical level of anxiety diagnosis is necessary for the cognitive
decline to be pronounced.
Perhaps the most convincing evidence identified by simple correlation is the increased
rate of AD development in patients who had been assessed as having CA a minimum of 10 years
prior to AD diagnosis (Gimson et al., 2018). This review by researchers Gimson et al. was able
to identify four examples of primary literature where this was the case; evidently, clinicallydiagnosed anxiety in these studies was well in advance of 5 to 6 years, disqualifying the
hypothesis that CA in these subjects was a prodromal symptom of AD. The limitations of this
study are obvious: only four examples of this significant relationship were found. Further
research should be undertaken to identify the correlation between CA diagnosis 10 years in
advance of AD development in order to strengthen the evidence of this relationship.
Furthermore, while the correlation between the development of these two pathologies may be
confidently said to exist, this still does not prove the causation of AD by CA. Rather, this
correlation should invite further research into the cellular pathophysiology of CA that might lend
itself to AD development, a topic which will be concluded about next using the current
knowledge base.
The next level of analysis regarding this issue is the effect of CA on brain structures that
might initiate conversion to AD. Convincing evidence comes from researchers Mah et al., who
identified anxiety as a significant predictor of conversion to AD from aMCI by analyzing
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Alzheimer’s ROI in imaging studies (Mah et al., 2015). This study highlighted the increased rate
of deterioration in the EC, and further hypothesized that this is the process by which anxiety
mediates the deterioration from MCI to AD. Additional and wider-reaching evidences should be
collected regarding the importance of the EC in anxiety-mediated deterioration in order to
increase the robustness of this hypothesis, yet this sizable study (n = 376) remains convincing.
Further brain imaging evidence highlights the increased frequency of hippocampal atrophy
among CA patients, namely those with PTSD (Villarreal et al., 2002; Weniger et al., 2008).
Hippocampal atrophy is a common pre-clinical occurrence witnessed in AD development, and
the atrophy of that brain region is progressive throughout the timeline of the disease (Carlesimo
et al., 2015; Fox et al., 1996). This combination of evidence might suggest a convincing causal
relationship between CA and AD, yet other research negates this premise for good reason. A
study of twins in which one twin experienced combat while the other did not determined smaller
hippocampal volume is more likely a cause of increased PTSD susceptibility, rather than PTSD
development being the cause of atrophy of the hippocampus (Lasko et al., 2002; Sapolsky,
2002). Further investigation of the relationship between hippocampal development and PTSD
diagnosis should be undertaken to characterize this relationship. The nature of twin studies might
suggest that the genotype of certain individuals could predispose them toward smaller
hippocampal volume and hence increased chance of developing PTSD, but more data is required
to make an informed conclusion.
The final level of analysis important in this issue is the cellular level. Research has been
identified that attributes a central role of GR signaling and hypersecretion of cortisol in
mediating the pathological effects of anxiety conditions, especially with relation to the
hippocampus. Firstly, certain PFC and other cerebral brain regions exhibit high instances of
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atrophy, supposedly mediated by increased concentration of GRs, making these regions
susceptible to cortisol hypersecretion (Goosens & Sapolosky, 2007). These regions are often
crucial endpoints of the RAS, a circuit of cholinergic communication that witnesses increased
deterioration in AD, and is the basis of clinical treatment with cholinesterase inhibitors (Hampel
et al., 2019; Hollander, Mohs, & Davis, 1986). This is a convincing correlation, but more
research should be undertaken targeting more specific regions of the cerebrum to determine if a
fundamental relationship exists. It would be essential to note the rate of deterioration of these
brain regions in MCI patients that convert to AD, and whether anxiety is a significant predictor
of increased deterioration. Furthermore, increased GC levels and HPA axis activity has been
associated with decreased LTP and hippocampal volume, becoming more pronounced with age
(Meaney et al., 1991; Pavlides et al., 1993). Higher GR levels are seen in hippocampal regions
with an increased rate of neuronal death (Goosens & Sapolosky, 2007). Some researchers
synthesize this evidence into the glucocorticoid cascade hypothesis. This proposes that excessive
levels of cortisol due to prolonged states of distress (seen in CA) lead to hippocampal cell death
and atrophy because of the neurotoxicity of these high cortisol levels; consequently, this atrophy
causes a decreased ability of the hippocampus to cope with cortisol levels by activating the
normal negative feedback mechanism wherein it down-regulates the secretion of cortisol via the
HPA axis. Therefore, the absence of this regulation leads to a detrimental positive feedback
mechanism of hyper cortisol secretion and hippocampal damage (Frodl & O'Keane, 2013).
Transition to AD pathology might be confirmed by the evidence that increased plasma cortisol
levels are seen in AD patients compared to normal controls (Armanini et al., 2003). The
previously mentioned researchers Frodl & O’Keane claimed neuroinflammation is also a result
of the glucocorticoid cascade hypothesis. This might contradict the normal effects of cortisol,
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which usually promotes decreased inflammation. Yet the neuroinflammatory consequences of
this cascade could be mediated by increased hippocampal cell death leading to cellular debris
accumulation; this hypothesis would need further testing of its validity. Regardless, if
neuroinflammation is seen as a result of excessive cortisol secretion, this could represent a
pathological mechanism leading to AD development that follows the Tau hypothesis: the
dysfunction of the CNS immune mechanisms in countering neuroinflammation causes the
aggregation of phosphorylated tau proteins (Maccioni et al., 2010).
Anxiety in Alzheimer’s Disease. The second half of this potential positive feedback
mechanism of pathologies must now be briefly analyzed and concluded about. In order to
conclude that AD increases the development of CA more so than the regular processes of
senescence, evidence should show that aberrant CNS development caused by AD is sufficient to
produce comorbid anxiety conditions, and that this anxiety is likely due to these developmental
malfunctions rather than the subjective distressing experience of the patients in question. This is
a difficult task at hand, and although certain convincing evidences exists, further experimental
investigation would aid in making such a conclusion.
Much evidence currently exists, however, for the increased proportion of anxiety
conditions and symptomatology in patients with AD than normal controls (Goyal et al., 2018;
Porter et al., 2003; Spalletta et al., 2010). Other researchers were more selective in including
only DSM-diagnosed conditions, yet they still found high instances of anxiety diagnosis (Ferretti
et al., 2001; Starkstein et al., 2007). A few researchers found a correlation, identifying increasing
anxiety as cognitive decline increased in rate, although not all studies corroborated this evidence
(Porter et al., 2003). More studies are necessary to obtain more conclusive data on this specific
aspect, but if this were proven true, this could support the hypothesis that increasing anxiety with
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cognitive decline is caused by the increase in plaque or NFT formation in the amygdala
throughout the six-stage progression of AD (Braak & Braak, 1991). This is significant evidence
of a possible causal relationship that requires further investigation.
As mentioned earlier, researchers España et al. further investigated the role of Aβ
accumulation in the amygdala in causing anxiety pathology. They noted that increased Aβ
concentration was associated with increased anxiety presentation, and highlighted the
dysfunction of GABAergic neurons in the BLA of both transgenic mice and humans with AD
(España et al., 2010). Given the paramount importance of GABAergic signaling (especially its
dysfunction in pathological conditions previously mentioned), this researcher provides
substantial direct evidence for a causal role of AD pathophysiology in producing anxiety
conditions. More investigation should be undertaken, specifically with regard to the mechanisms
by which Aβ accumulation or the oxidative stress caused thereof mediates the negative effect on
fear acquisition via the ERK/MAPK signaling pathway in the BLA.
Conclusion
Conclusively, substantial evidence has been presented to identify the interrelatedness of
these two pathologies, CA and AD. Defining the exact mechanism by which these two CNS
dysfunctions have a hand in causing the other has been more difficult. Sizeable reviews of the
pathophysiology behind each disorder have shown significant overlap between these diseases in
critical areas. A few investigators sought to answer research questions specific to these areas of
overlap, and have thus identified potential methods of defining the mechanisms by which these
diseases are related on a cellular level. However, the proposed positive feedback mechanism
between CA and AD would benefit from additional evidences, of which a few can be identified.
Firstly, additional clinical studies should seek to identify evidence of AD development at least 10
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years from baseline anxiety diagnosis to further support the correlation between CA and AD and
exclude the interference of prodromal stage symptoms. More research is also required in
determining the importance of the entorhinal cortex in anxiety-mediated deterioration during
AD. Likewise, future work should determine if the rate of deterioration of the PFC in patients
that convert from MCI to AD is significantly increased by the presence of anxiety. Determining
the cause of neuroinflammation that might initiate the cascade of tau-phosphorylation is of the
utmost importance; the hypothesis that hippocampal cell death caused by the glucocorticoid
cascade mediates neuroinflammation requires further investigation. Furthermore, it would be
essential to note if anxiety increase in AD is paralleled by increasing aggregation of NFTs in the
amygdala. Lastly, the effect of Aβ accumulation in the BLA on the ERK/MAPK pathway of fear
acquisition should be investigated. Scientific investigation and discovery in these areas could
enable researchers to clarify the relationship between these two pathologies. If a further
understanding of the identified correlations is brought about, clinicians could introduce new
treatments to patients suffering from anxiety or AD with respect to the relationship between
these conditions.
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